NASDAQ · URGN

UroGen Pharma Ltd.

$41.46 +$0.49 (+1.20%) 1D After hours
Charting by TradingView

Key Metrics

$2.00B
Market cap
—
P/E · TTM
$140.49M
Revenue · TTM
−$133.23M
Net income
EPS · TTM $-2.81
Dividend yield —
Free cash flow −$166.04M
Beta · 1Y 1.21
EBITDA · TTM −$138.00M
Gross margin 89.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 8
    The stock moved +10.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8
  • Mar 2
    The stock moved -12.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.00B
Enterprise value$2.04B
Shares outstanding48.7M
52-wk range$15.86 – $43.93
Avg volume · 20D512.1K
Net cash −$39.82M
Book value / share$-2.62
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About UroGen Pharma Ltd.
IPO dateMay 4, 2017
Employees291

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S14.21
P/FCF—
EV/EBITDA—
EV/Sales14.49
Graham №—

Profitability

Gross 89.9%
Operating -98.4%
Net -94.8%
FCF -118.2%
ROE / ROIC 107.2% · 157.8%

Financial Health

Current ratio4.69
Quick ratio4.28
Debt / equity-1.53
Debt / EBITDA -1.37
Net cash −$39.82M
Working capital$186.83M

Cash Flow · TTM

Operating CF −$165.74M
Capex −$299.00K
Free cash flow −$166.04M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-2.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings